A new drug for the treatment of Bekhterev's disease is successfully undergoing the third phase of clinical trials. This was announced by the director of the Nasonova Research Institute of Rheumatology, Corresponding Member of the Russian Academy of Sciences Alexander Lila.
Such a drug was developed by the domestic company «Biocad» and has been undergoing clinical trials for several years. Today, we are completing the second phase, the third phase is underway, and in these two phases, more than 600 patients in the Russian Federation are already receiving this drug.
The drug is prescribed to patients who have not undergone treatment using genetic engineering therapy. Currently, four medical centers in Moscow, St. Petersburg and Novosibirsk are conducting such therapy in hospitals.
The drug is administered intravenously via a drip. The second infusion — drug administration — is carried out three months after the first, and then every six months. Treatment can continue for several years, but patients can lead a full life.
Bekhterev's disease — is a chronic disease of the spine and joints. Its main symptoms are: lower back pain, which worsens at night and in the morning, and stiffness of movements. Most often, the disease affects young men, the exact cause of the disease is unknown, a key role is played by genetic predisposition.
Read more materials on the topic:
- An analogue of a foreign drug for the treatment of thrombosis was created at SibGMU
- The first domestic analogue of the American drug against head cancer "Cetuximab" received registration from the Ministry of Health
- AI for diagnosing brain tumors was created by scientists from NNSU
Now on home
Zavoz.Pro produces muzzle brakes-compensators made of stainless heat-resistant steel
The technology allows simultaneous purification of raw materials and obtaining an ingredient with a high potassium content
The special clothing has positive buoyancy and will protect against hypothermia in water for an hour
Expert Polina Albek: Only Our Designers Are Capable of Implementing Such a Project
Testing of the modernized aircraft will take about a year and a half
Military expert Boris Rozhin: the drone is capable of hitting the most protected targets
The material withstands loads up to 106 MPa and is suitable for bridges, roads, and heavy equipment
The complex combines air defense and electronic warfare systems into a single loop and responds without human intervention
The medical device was developed by specialists from the Samara Medical University
The new RGT facility allows for the complete restoration of key hot section components